Merck (MRK) and Eisai Announces EU Approval of LENVIMA Plus KEYTRUDA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. NVDA
3. ONON
4. PSKY
5. META
6. VRTX
7. LGND
8. MA
9. ACN
10. IAUX

Go back to Merck (MRK) and Eisai Announces EU Approval of LENVIMA Plus KEYTRUDA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Merck & Co. (NYSE: MRK) Delayed: 150.43 +0.93 (0.62%)
Previous Close $149.50    52 Week High $65.46 
Open $148.69    52 Week Low $47.97 
Day High $150.50    P/E 102.33 
Day Low $148.04    EPS $1.47 
Volume 926,298